[{"id":"456efb5b-1647-4ddb-add1-645fa0cf138f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06542588","created_at":"2025-02-26T07:12:34.732Z","updated_at":"2025-02-26T07:12:34.732Z","phase":"Phase 2","brief_title":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC","source_id_and_acronym":"NCT06542588","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hetronifly (serplulimab) • pimurutamab (HLX07)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/19/2024","start_date":" 07/19/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-18"},{"id":"2f7123d3-059b-467b-a21a-258e54ebdc19","acronym":"","url":"https://clinicaltrials.gov/study/NCT04297995","created_at":"2021-01-18T20:51:01.364Z","updated_at":"2024-07-02T16:35:40.677Z","phase":"Phase 2","brief_title":"Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors","source_id_and_acronym":"NCT04297995","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • 5-fluorouracil • Hetronifly (serplulimab) • pimurutamab (HLX07)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 131","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-08-08"},{"id":"98970909-3c82-4ba3-b547-a6d90787bc2e","acronym":"HLX07Ib/II","url":"https://clinicaltrials.gov/study/NCT03577704","created_at":"2021-01-18T17:36:07.923Z","updated_at":"2024-07-02T16:35:50.858Z","phase":"Phase 1/2","brief_title":"The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.","source_id_and_acronym":"NCT03577704 - HLX07Ib/II","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1 • PD-1 • CTLA4 • IL2RA • TNFRSF9","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • CTLA4 • IL2RA • TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • paclitaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • pimurutamab (HLX07)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 08/08/2018","start_date":" 08/08/2018","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2023-04-12"},{"id":"967c74ff-8419-40c4-b0d2-df73293b697e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05221658","created_at":"2022-02-05T18:29:07.075Z","updated_at":"2024-07-02T16:36:04.805Z","phase":"Phase 2","brief_title":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC","source_id_and_acronym":"NCT05221658","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • Hetronifly (serplulimab) • pimurutamab (HLX07)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/25/2022","start_date":" 08/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 08/30/2025","study_completion_date":" 08/30/2025","last_update_posted":"2022-08-29"},{"id":"8845b984-11a1-4717-8120-2e8e94f20777","acronym":"","url":"https://clinicaltrials.gov/study/NCT05215925","created_at":"2022-02-05T18:27:53.813Z","updated_at":"2024-07-02T16:36:07.686Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression","source_id_and_acronym":"NCT05215925","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel • pemetrexed • pimurutamab (HLX07)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 07/15/2023","primary_completion_date":" 07/15/2023","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2022-07-06"},{"id":"ec3d7f76-4788-422e-bc96-64cb9001ae68","acronym":"","url":"https://clinicaltrials.gov/study/NCT04976647","created_at":"2021-07-26T17:53:23.941Z","updated_at":"2024-07-02T16:36:10.872Z","phase":"Phase 2","brief_title":"A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC","source_id_and_acronym":"NCT04976647","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Hetronifly (serplulimab) • pimurutamab (HLX07)"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 01/18/2022","start_date":" 01/18/2022","primary_txt":" Primary completion: 01/30/2023","primary_completion_date":" 01/30/2023","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2022-05-06"},{"id":"1095406d-ef04-44b1-977e-b425f698a2fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05239650","created_at":"2022-02-15T16:53:09.459Z","updated_at":"2024-07-02T16:36:11.071Z","phase":"Phase 2","brief_title":"Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC","source_id_and_acronym":"NCT05239650","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • Hetronifly (serplulimab) • pimurutamab (HLX07)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/15/2022","start_date":" 07/15/2022","primary_txt":" Primary completion: 10/15/2025","primary_completion_date":" 10/15/2025","study_txt":" Completion: 10/15/2026","study_completion_date":" 10/15/2026","last_update_posted":"2022-05-03"},{"id":"4fbce8cd-e341-444b-9d17-0abce901d468","acronym":"","url":"https://clinicaltrials.gov/study/NCT05246982","created_at":"2022-02-18T13:52:44.712Z","updated_at":"2024-07-02T16:36:11.152Z","phase":"Phase 2","brief_title":"HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer","source_id_and_acronym":"NCT05246982","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • Hetronifly (serplulimab) • pimurutamab (HLX07)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/23/2022","start_date":" 03/23/2022","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 03/30/2024","study_completion_date":" 03/30/2024","last_update_posted":"2022-05-02"}]